TLRY Quote, Financials, Valuation and Earnings

Edesa Biotech has a net margin of -13.81% compared to Tilray Brands's net margin of --. Tilray Brands's return on equity of -7.24% beat Edesa Biotech's return on equity of --.

Tilray Brands has a consensus price target of $2.18, signalling upside risk potential of 54.39%. On the other hand Edesa Biotech has an analysts' consensus of $20.50 which suggests that it could grow by 1071.43%. Given that Edesa Biotech has higher upside potential than Tilray Brands, analysts believe Edesa Biotech is more attractive than Tilray Brands.

Tilray Brands has a beta of 2.084, which suggesting that the stock is 108.36% more volatile than S&P 500. In comparison Edesa Biotech has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.837%.

Tilray Brands has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tilray Brands pays -- of its earnings as a dividend. Edesa Biotech pays out -- of its earnings as a dividend.

Tilray Brands quarterly revenues are $229.9M, which are larger than Edesa Biotech quarterly revenues of --. Tilray Brands's net income of -$31.7M is lower than Edesa Biotech's net income of -$962.1K. Notably, Tilray Brands's price-to-earnings ratio is -- while Edesa Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tilray Brands is 1.37x versus 17.02x for Edesa Biotech. Usually stocks with elevated PS ratios are considered overvalued.

ESSA Pharma has a net margin of -13.81% compared to Tilray Brands's net margin of --. Tilray Brands's return on equity of -7.24% beat ESSA Pharma's return on equity of --.

Tilray Brands has a consensus price target of $2.18, signalling upside risk potential of 54.39%. On the other hand ESSA Pharma has an analysts' consensus of -- which suggests that it could grow by 489.17%. Given that ESSA Pharma has higher upside potential than Tilray Brands, analysts believe ESSA Pharma is more attractive than Tilray Brands.

Tilray Brands has a beta of 2.084, which suggesting that the stock is 108.36% more volatile than S&P 500. In comparison ESSA Pharma has a beta of 1.624, suggesting its more volatile than the S&P 500 by 62.388%.

Tilray Brands has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ESSA Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tilray Brands pays -- of its earnings as a dividend. ESSA Pharma pays out -- of its earnings as a dividend.

Tilray Brands quarterly revenues are $229.9M, which are larger than ESSA Pharma quarterly revenues of --. Tilray Brands's net income of -$31.7M is lower than ESSA Pharma's net income of -$6.4M. Notably, Tilray Brands's price-to-earnings ratio is -- while ESSA Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tilray Brands is 1.37x versus -- for ESSA Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience has a net margin of -13.81% compared to Tilray Brands's net margin of -2121.06%. Tilray Brands's return on equity of -7.24% beat Lexaria Bioscience's return on equity of -93.31%.

Tilray Brands has a consensus price target of $2.18, signalling upside risk potential of 54.39%. On the other hand Lexaria Bioscience has an analysts' consensus of -- which suggests that it could grow by 352.49%. Given that Lexaria Bioscience has higher upside potential than Tilray Brands, analysts believe Lexaria Bioscience is more attractive than Tilray Brands.

Tilray Brands has a beta of 2.084, which suggesting that the stock is 108.36% more volatile than S&P 500. In comparison Lexaria Bioscience has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.234%.

Tilray Brands has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tilray Brands pays -- of its earnings as a dividend. Lexaria Bioscience pays out -- of its earnings as a dividend.

Tilray Brands quarterly revenues are $229.9M, which are larger than Lexaria Bioscience quarterly revenues of $84K. Tilray Brands's net income of -$31.7M is lower than Lexaria Bioscience's net income of -$1.8M. Notably, Tilray Brands's price-to-earnings ratio is -- while Lexaria Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tilray Brands is 1.37x versus 58.77x for Lexaria Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals has a net margin of -13.81% compared to Tilray Brands's net margin of --. Tilray Brands's return on equity of -7.24% beat Xenon Pharmaceuticals's return on equity of --.

Tilray Brands has a consensus price target of $2.18, signalling upside risk potential of 54.39%. On the other hand Xenon Pharmaceuticals has an analysts' consensus of $57.67 which suggests that it could grow by 50.1%. Given that Tilray Brands has higher upside potential than Xenon Pharmaceuticals, analysts believe Tilray Brands is more attractive than Xenon Pharmaceuticals.

Tilray Brands has a beta of 2.084, which suggesting that the stock is 108.36% more volatile than S&P 500. In comparison Xenon Pharmaceuticals has a beta of 1.189, suggesting its more volatile than the S&P 500 by 18.926%.

Tilray Brands has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tilray Brands pays -- of its earnings as a dividend. Xenon Pharmaceuticals pays out -- of its earnings as a dividend.

Tilray Brands quarterly revenues are $229.9M, which are larger than Xenon Pharmaceuticals quarterly revenues of --. Tilray Brands's net income of -$31.7M is higher than Xenon Pharmaceuticals's net income of -$62.8M. Notably, Tilray Brands's price-to-earnings ratio is -- while Xenon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tilray Brands is 1.37x versus 221.08x for Xenon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.